Phase Ib/II study of safety and efficacy of low‐dose decitabine‐primed chemoimmunotherapy in patients with drug‐resistant relapsed/refractory alimentary tract cancer

The pressing need for improved therapeutic outcomes provides a good rationale for identifying effective strategies for alimentary tract (AT) cancer treatment. The potential re‐sensitivity property to chemo‐ and immunotherapy of low‐dose decitabine has been evident both preclinically and in previous...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Meixia, Nie, Jing, Liu, Yang, Li, Xiang, Zhang, Yan, Brock, Malcolm V., Feng, Kaichao, Wu, Zhiqiang, Li, Xiaolei, Shi, Lu, Li, Suxia, Guo, Mingzhou, Mei, Qian, Han, Weidong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Cancer Therapy and Prevention
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6099263/
https://www.ncbi.nlm.nih.gov/pubmed/29663379
http://dx.doi.org/10.1002/ijc.31531

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6099263/
https://www.ncbi.nlm.nih.gov/pubmed/29663379
http://dx.doi.org/10.1002/ijc.31531

Ejemplares similares